INTRODUCTION {#sec0005}
============

Duchenne muscular dystrophy (DMD) is usually diagnosed at age 3--5 years when children start to show signs of muscle weakness. Loss of ambulation is the first irreversible disease milestone, typically occurring during early teenage years. Coinciding with loss of ambulation, pulmonary function starts to decline and ultimately progresses to the stage of chronic respiratory failure with patients requiring assisted ventilation, initially nocturnal and then diurnal and finally continuously. Becoming dependent on assisted ventilation represents a key irreversible disease milestone for patients with DMD, occurring years after loss of ambulation. Despite major progress in patient care including ventilator support \[[@ref001]\], cardio-pulmonary complications remain the major cause of morbidity and early mortality in DMD \[[@ref002]\].

Clinical complications from respiratory muscle weakness include inability to cough efficiently, leading to poor airway clearance and mucus plugging of airways, recurrent respiratory infections, which frequently require hospitalization, and respiratory failure resulting in the need of ventilator support \[[@ref006]\]. DMD patients and their caregivers consider the preservation of pulmonary function, particularly maintaining effective cough and reducing the risk of airway infections, important treatment goals \[[@ref007]\]. Safeguarding pulmonary function, therefore, represents a significant unmet need.

As emphasized by several standard of care recommendations and guidelines \[[@ref002]\] serial assessment of pulmonary function is a critical element of routine monitoring for patients with DMD, especially when they become non-ambulant. The most frequently used pulmonary function parameters across all age ranges are the volume-related forced-vital capacity (FVC) and the flow-related peak expiratory flow (PEF), typically measured by spirometry during hospital visits. To account for maturational changes, pulmonary function outcomes are normalized to patient age, height, gender and race and expressed as percent of predicted (PEF% p, FVC% p). Ulna length is routinely used in clinical practice to derive a surrogate measure of patient height for normalization of pulmonary function testing results \[[@ref011]\], particularly in patients who have become non-ambulant, have developed joint contractures and are unable to stand upright. Although effort-dependent, FVC% p and PEF% p can reliably be measured in school age patients as shown by low within-subject coefficients of variation (CV) for successive measures \[[@ref014]\]. Several studies have independently demonstrated that PEF% p and FVC% p follow a co-linear decline between the age of around 10--20 years \[[@ref015]\]. Recent studies also indicate that PEF% p might be a more sensitive measure of early decline in pulmonary function since PEF% p begins to decline before FVC% p \[[@ref016]\] and in contrast to FVC% p decline in PEF% p can be seen already in ambulant patients \[[@ref020]\].

Standard of care guidelines recommend regular monitoring of pulmonary function and command change in patient care when decline in pulmonary function drops below defined thresholds \[[@ref002]\]. However, as recently demonstrated in a study with 770 DMD patients from Europe and the US, compliance for routine pulmonary function monitoring is generally poor \[[@ref021]\]. Specifically, this study found that depending on country only in 61--81% of patients the guideline of 6-monthly pulmonary function monitoring was fulfilled.

Therefore, there is a need for a more versatile, ideally home-based approach to obtain pulmonary function data from patients with DMD. Such data, if collected regularly, could provide treating physicians an indicator of the rate of pulmonary function decline and help identify patients at risk of falling below clinically relevant thresholds of pulmonary function, which would then indicate the need for a change in clinical management. In addition, more frequent home-based assessments of pulmonary function may offer statistical advantages for the evaluation of treatment effects in clinical trials.

In this study we evaluated the use of a versatile, child-compatible hand-held device (HHD) that DMD patients could apply for pulmonary function testing at home. We hypothesized that home-based spirometry is feasible as defined by adherence to the procedure, and we further hypothesized that weekly home spirometry would produce comparable trends to data collected by in-clinic spirometry testing.

METHODS {#sec0010}
=======

Clinical trial conduct {#sec0015}
----------------------

The randomized, placebo-controlled, Phase III DELOS study of idebenone in patients with DMD was conducted between July 2009 and December 2013 in study centres located in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, Italy, Spain, and the USA. The trial and any changes to the protocol were approved by relevant national authorities and the institutional review boards or independent ethics committees in the countries of the participating centers and conducted in accordance with good clinical practice and the principles of the Declaration of Helsinki. Prior to any study related procedure, written informed consent was obtained from all patients and/or parents or guardian. The DELOS trial (clinicaltrials.gov ID: NCT01027884) had the objective to assess the efficacy of idebenone, compared to placebo, in improving or delaying the loss of respiratory function in patients with DMD. The study design and overall results have been previously published \[[@ref022]\]. The study met its primary endpoint and demonstrated a statistically significant and clinically relevant reduction of pulmonary function decline, as measured by the primary endpoint, change to week 52 in PEF% p, using in-clinic spirometry testing. Further work reported analyses of the efficacy of idebenone treatment on respiratory complications \[[@ref023]\] and inspiratory function \[[@ref025]\] as well as a detailed characterisation of the baseline status of enrolled patients and the progression of pulmonary function loss in the placebo group \[[@ref014]\].

Methods of pulmonary function testing {#sec0020}
-------------------------------------

To ensure the collection of reliable pulmonary function data, the DELOS study protocol only allowed enrolment of patients who were able to perform a tight mouth seal. In addition, patients had to provide reproducible PEF% p results between screening and baseline (completed within 6 weeks after screening) with a variability of less than 15% in PEF% p. The observed coefficient of variation between screening and baseline was 6.97% for PEF% p which was comparable to a coefficient of variation of 6.69% for FVC% p \[[@ref014]\]. Assessment of PEF% p was performed by two independent methods at different intervals and frequency. The primary analysis of changes in PEF% p was based on in-clinic spirometry conducted at baseline and weeks 13, 26, 39 and 52 using a Pneumotrac Spirometer 6800 (Vitalograph). Independently, PEF% p data were also collected weekly at home with the portable, child compatible electronic pulmonary monitoring device (asma-1/nmd-1; usb model 4000; Vitalograph) which was used with a disposable tube-shaped cardboard mouthpiece ([Fig. 1](#jnd-5-jnd180338-g001){ref-type="fig"}).

![Hand-held device (HHD) and mouthpiece used in this study.](jnd-5-jnd180338-g001){#jnd-5-jnd180338-g001}

This hand-held device (HHD) is a validated, battery powered, portable electronic peak flow meter for monitoring pulmonary function applying a stator/rotor mass flow principle to measure PEF. The flow range for PEF is 25--840 L/min, device accuracy is better than +/--10% or +/--25 L/min, whichever is greater and device repeatability is better than 5% or 10 L/min, whichever is greater. This HHD is CE-marked in accordance with the EU Medical Devices Directive 2007/47/EC, has FDA 510k registration and was tested to meet accuracy and precision as specified by the American Thoracic Society (ATS) and European Respiratory Society (ERS) 2005 recommendations \[[@ref026]\]. The device precludes unintentional manipulation of stored data.

Collection of pulmonary function data {#sec0025}
-------------------------------------

At each hospital visit of the DELOS study the assessment of PEF was the first pulmonary function test to be conducted by spirometry. For the PEF-manoeuvre, study participants were instructed to exhale all of the air out of the lung as fast as possible, until the lungs are completely empty. The highest available test result of PEF (in L/min) was used for further analysis and PEF% p calculated centrally by using patient ulna length data to derive patient height \[[@ref022]\].

At the study start patients and caregivers were instructed and trained by a physician, physical therapist or study nurse on the use of the HHD, which was to be conducted once per week at home, preferentially on a specified day. Patients received monthly phone calls from the study co-ordinator to remind them to perform the tests with the HHD. In addition to the home-based PEF assessments, patients were asked to perform pulmonary function test with the HHD at each hospital visit following the spirometry test. During each study site visit, all data recorded on the HHD were downloaded via USB connection and transferred to the study database.

Normalization of pulmonary function data to percent or predicted (% p) {#sec0030}
----------------------------------------------------------------------

For each pulmonary function test (either in-clinic spirometry or with HHD), the highest value from a minimum of three and up to five consecutive manoeuvres was used for analysis. To calculate PEF% p, raw data of PEF (measured in L/min) were normalized for height (derived from ulnar length \[[@ref012]\], using established conversion equations \[[@ref027]\] (for details see \[[@ref022]\]).

Data analyses {#sec0035}
-------------

Analyses were conducted in the ITT population, except for the linear regression analysis ([Fig. 2](#jnd-5-jnd180338-g002){ref-type="fig"}: Method 1), where 4 patients did not provide data for up to at least Month 6 and for the MMRM analysis of all weekly data ([Fig. 2](#jnd-5-jnd180338-g002){ref-type="fig"}, Method 4), where 6 patients did not provide a baseline value). Individual adherence to the device was assessed by calculating the proportion of weeks that a patient provided HHD data divided by the number of study weeks with exposure to study medication. For subjects who discontinued the study, HHD data was used up to the day of last medication intake. Results from the HHD device (individual measurements) and the progression over 52 weeks were also compared graphically with the results from spirometry data collected in 3-monthly intervals during clinic visits. To assess how well the individual regression lines fitted the HDD data, we calculated the mean percental residuals over all data points per subject and categorized this value into up to 5%, between 5% and 10% and over 10%. For a subject in the \<5% category, the mean deviation of all measurements from the regression line was less than \<5%.

![Illustration of four methods (M1 to M4) applied to analyse HDD data.](jnd-5-jnd180338-g002){#jnd-5-jnd180338-g002}

Data from the HHD was analysed using four different statistical methods (see [Fig. 2](#jnd-5-jnd180338-g002){ref-type="fig"}).

Method 1: For the pre-defined primary analysis of HDD data in the DELOS trial, linear regression slopes were fitted for every individual subject, using all available weekly HHD measurements. The individual slopes were then analysed with an ANCOVA model using the intercept of the regression as Baseline covariate.

Method 2: HDD values obtained from the in-clinic measurements were analysed with a mixed model for repeated measures (MMRM), using the baseline value as covariate. The main purpose of this analysis was to allow direct comparison between HHD-derived data and hospital spirometry data obtained at the same day during study site visit.

Method 3: For this window-based approach an analogous MMRM analysis was performed similar to Method 2. However, for this method, the mean values from all HHD data available from the 3-weeks before and after the study site visits was calculated. For the visits at study start only the 3 weeks following the baseline visit were included and for the week 52 visit only the 3-weeks prior to this last study visit were used. Sensitivity analyses using a similar approach were conducted using 2-week and 4-week windows.

Method 4: A repeated measures MMRM analysis was conducted using all weekly data collected with the HHD. In this case study week was used as fixed factor.

The primary endpoint in the DELOS trial was the difference between treatment groups for the change in PEF % p from Baseline to the week 52-time point, assessed by an MMRM using the treatment group contrast at the week 52-time point \[[@ref022]\]. The primary method for analysing HHD data (linear regression) assesses the overall progression and separation of the treatment groups during the study period, not restricted to the week 52-time point. For an appropriate comparison, for Methods 2--4 also the overall study treatment differences were calculated (assessed by the overall study treatment group contrast).

Statistical analyses were conducted using R 3.4.4 \[[@ref028]\] and SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).

RESULTS {#sec0040}
=======

Patients {#sec0045}
--------

Detailed demographic characteristics and baseline pulmonary function of the DELOS study population were previously published \[[@ref014]\]. Briefly, patients with DMD enrolled in the DELOS trial were between 10 and 18 years of age (mean: 14 years) and were required to be off glucocorticoids (GC) for at least 1 year prior to enrolment and GC use was excluded during the 52-week study period. Patients with asthma, bronchitis/COPD, bronchiectasis, emphysema, pneumonia or the presence of any other non-DMD respiratory illness that affects pulmonary function testing were also excluded (see \[[@ref022]\] for details on inclusion/exclusion criteria). All patients in the study were able to perform the pulmonary function testing with the HHD. Study participants had to be in the pulmonary function decline stage, assessed as PEF% p of≤80% at screening (and confirmed at baseline). Patients enrolled into DELOS presented with advanced stage of the disease as assessed by upper and lower extremity weakness: Brooke upper extremity score was 4.2±1.2 (mean, SD) with 59.4% of patients unable to raise their hand to the mouth (Brooke score 5 or 6); 92.2% of study participants were non-ambulant at baseline \[[@ref014]\]. In total, 64 patients were randomized, 31 patients received idebenone (Raxone^®^ 150 mg tablets, Santhera Pharmaceuticals) at a daily dose of 900 mg (given as 3 times 300 mg taken with meals) and 33 received placebo. Randomization was stratified according to baseline PEF% p value (PEF% p \<40% or 40 to 80%).

Adherence to the HHD {#sec0050}
--------------------

Adherence to the use of the HHD was assessed by calculating the number of weeks a patient provided HDD data divided by the number of weeks of exposure to study medication ([Fig. 3](#jnd-5-jnd180338-g003){ref-type="fig"}). Overall mean adherence in the use of the HHD was calculated by weighted mean of individual adherences, as summarised in [Table 1](#jnd-5-jnd180338-t001){ref-type="table"}.

###### 

Adherence to pulmonary function assessment using the HHD device

  Group                   Adherence to HHD use[^\*^](#tfn1){ref-type="table-fn"}
  ---------------------- --------------------------------------------------------
  Idebenone (*n* = 31)                       76.3% (SD 22.0)
  Placebo (*n* = 33)                         75.5% (SD 21.1)
  Total (*n* = 64)                           75.9% (SD 21.5)

^\*^ Data is weighted mean (Standard Deviation, SD) of percentage of weeks in study with at least one home-based measurement.

![Distribution of adherence to HHD pulmonary function testing. Vertical lines indicate overall median adherence value.](jnd-5-jnd180338-g003){#jnd-5-jnd180338-g003}

During this study a total of 2689 PEF-measures (counting only the highest available PEF measure from each daily test) were collected. Overall adherence to the weekly use of the HHD was very good with over 75% overall, which suggests that on average a patient missed 8 weekly measurements during the 52-week study period. Only 8 patients (4 on idebenone and 4 on placebo) had an adherence of less than 50% ([Fig. 3](#jnd-5-jnd180338-g003){ref-type="fig"}). Variability in the adherence of HHD use was study-site specific: whilst overall compliance was well above 75% (in centres with more than 3 patients), there was one study site with five patients with a mean adherence of 35%, which might have resulted from inappropriate instructions provided by study site personnel to participants. In addition, we assessed adherence on a weekly and quarterly basis over the course of the 52-week study period ([Fig. 4](#jnd-5-jnd180338-g004){ref-type="fig"}).

![Weekly and quarterly adherence to the HDD pulmonary function testing during the 52-week study period. Small dots indicate weekly average adherence, and connected large dots show mean quarterly adherence by treatment group. The dotted line shows overall mean compliance (75.9%).](jnd-5-jnd180338-g004){#jnd-5-jnd180338-g004}

Adherence was around 80% in the first quarter in both treatment groups, and remained relatively stable at approximately 75% in the idebenone group throughout the remaining study period. In the placebo group, adherence dropped to 71% in the third quarter and eventually to 67% in the fourth quarter of the study ([Fig. 4](#jnd-5-jnd180338-g004){ref-type="fig"}). We tested whether the slightly lower and declining adherence in the placebo group could have been a consequence of the declining pulmonary function and resulting discouragement of study participants from regularly conducting the home-based testing. A correlation analysis (not shown) did not reveal reduced adherence in patients with declining pulmonary function. In summary, these data indicate that patients were generally comfortable using this HHD during the 52-week study period and the overall adherence was good.

Comparison of pulmonary function results obtained by HHD with in-clinic spirometry results and intra-subject variability {#sec0055}
------------------------------------------------------------------------------------------------------------------------

PEF% p data obtained with the HHD from exemplary individuals are shown in [Fig. 5](#jnd-5-jnd180338-g005){ref-type="fig"} and compared to results obtained by spirometry during study visits at baseline and weeks 13, 26, 39 and 52. From this visual inspection of all available data obtained by in-clinic spirometry and HHD per subject (as shown in [Fig. 5](#jnd-5-jnd180338-g005){ref-type="fig"}) it can be concluded that data obtained by HHD match very well the data obtained by hospital spirometry. For the majority of patients (41, 64%) the mean percental residuals were less than 5% (examples in [Fig. 5](#jnd-5-jnd180338-g005){ref-type="fig"}A). For another 21 (33%) it was between 5% and 10% ([Fig. 5](#jnd-5-jnd180338-g005){ref-type="fig"}B) and only for 2 patients (3%) the mean of percental residuals was larger than 10% ([Fig. 5](#jnd-5-jnd180338-g005){ref-type="fig"}C). For these two patients the HDD data suggests that in certain phases of the study the home-based measurements deviated from hospital-based spirometry data.

![PEF% p data obtained by HHD from 6 representative patients. Weekly HHD data are shown as coloured dots (orange, top row: patients receiving idebenone, grey, bottom row: patients receiving placebo). Linear regression lines derived from HHD data (colored line), and derived from hospital based spirometry data (black dots and black line) are shown for comparison.](jnd-5-jnd180338-g005){#jnd-5-jnd180338-g005}

To further assess the comparability of PEF% p data obtained by spirometry and by HHD, data obtained with both methods at the same day during hospital visits at Baseline and week 13, 26, 39 and 52 were correlated. The resulting Spearman's rho correlations were 0.89 (*p* \< 0.001) for PEF \[L/min\] and 0.80 (*p* \< 0.001) for PEF% p, indicating overall very good data correlation between spirometry and HHD assessments.

Comparative analysis between spirometry- and HHD-assessed data for the treatment effect of idebenone on PEF% p {#sec0060}
--------------------------------------------------------------------------------------------------------------

The DELOS study investigated the effect of idebenone compared to placebo for the change in PEF% p from baseline to week 52. The primary endpoint was the difference between treatment groups for hospital spirometry measured PEF% p and calculated by a mixed model for repeated measures. As described previously \[[@ref022]\], the rate of decline for PEF% p was higher (--8.84% p) in the placebo group compared to the idebenone group (--2.57% p), resulting in a statistically significant between-treatment group difference in favour of idebenone of 6.27% p at week 52 and of 6.52% p when all post-baseline visits were used for the calculation ([Table 2](#jnd-5-jnd180338-t002){ref-type="table"}).

###### 

Comparative analyses for spirometry- and HHD-assessed outcomes for the effect of idebenone on the change PEF% p

                                                   Assessment method        Treatment group (n)      PEF% p (baseline)^3^     Change from baseline to week 52^4^   Treatment Difference at week 52^4^   Treatment Difference Overall ^4,5^
  ------------------------------------------ ----------------------------- ---------------------- -------------------------- ------------------------------------ ------------------------------------ ------------------------------------
                                               Hospital-based Spirometry    Idebenone (*n* = 31)         53.5 (10.3)                --2.57 (--6.68, 1.54)           6.27 (0.61, 11.93) *p* = 0.0306      6.52 (1.98, 11.06) *p* = 0.0056
                                              (Primary Study Endpoint)^1^    Placebo (*n* = 33)          54.2 (13.2)               --8.84 (--12.73, --4.95)                                            
  Data from HHD                                       *Method 1*            Idebenone (*n* = 30)         53.9 (10.6)                --2.48 (--7.39, 2.44)                    not applicable             6.84 (--0.15, 13.83) *p* = 0.0548
  Linear Regression Analysis                      Placebo (*n* = 30)            50.1 (14.8)        --9.32 (--14.2, --4.40)                                                                             
  *Method 2*                                     Idebenone (*n* = 25)           52.9 (11.5)         --0.08 (--6.07, 5.91)      9.73 (1.52, 17.94) *p* = 0.0211      7.48 (2.00, 12.96) *p* = 0.0085    
  Measurement at hospital visit                   Placebo (*n* = 27)            54.2 (13.2)        --9.81(--15.42, --4.20)                                                                             
  *Method 3*                                     Idebenone (*n* = 31)           53.1 (12.3)         --1.77 (--6.38, 2.84)      7.24 (0.82, 13.66) *p* = 0.0277       4.72 (0.45, 8.99) *p* = 0.0310    
  Window-based approach^2^ (3 week period)        Placebo (*n* = 31)            51.8 (14.8)        --9.01 (--13.48, --4.55)                                                                            
  *Method 4*                                     Idebenone (*n* = 27)           55.6 (12.6)             not applicable                  not applicable               5.60 (2.16, 9.04) *p* = 0.0018    
  All individual weekly measurements              Placebo (*n* = 31)            52.8 (14.7)             not applicable                                                                                 

Method 1--4: analyses methods as described in [Fig. 2](#jnd-5-jnd180338-g002){ref-type="fig"}. 1: as reported in (Buyse et al., 2015); 2: data averaged from a time window±3 weeks around hospital visits; 3: data is mean (SD); 4: data is estimated mean from MMRM (95% CI); 5: for the treatment difference overall, all post-baseline values were included in the model.

When these data are compared to results obtained with the HHD at the hospital visits (Method 2), the observed between-treatment group difference in favour of idebenone for PEF% p was 9.73% p for the change to week 52 and 7.48% p for the analysis including all post-baseline visits. These outcomes are in the same range but numerically larger than the treatment difference observed by hospital spirometry. From additional methods used to analyse HHD-derived data (regression analysis, window-based approach and all individual weekly assessments, Method 1, 3 and 4) it appears that linear regression analysis matches best the results obtained by hospital-based spirometry outcomes. The window-based analysis approach (using a 3-week window) reasonably matched the spirometry analysis at week 52 but underestimated the treatment effect of idebenone when all post-baseline data are included. Using the analysis with all individual post-baseline data (Method 4), also slightly underestimated the idebenone treatment effect compared to in-clinic spirometry results.

A graphical by-patient comparison for the change in PEF% p from baseline to week 52 between in-clinic spirometry results and HHD data analysed by linear regression analysis (Method 1) is shown in [Fig. 6](#jnd-5-jnd180338-g006){ref-type="fig"}. In general the 12-month changes in PEF% p assessed by these methods match very well. There were only 8 patients for whom the change in PEF% p over the 12-month study period deviated by more than 20% between in-clinic spirometry and HHD-assessed results.

![Scatterplot for individual patients (N = 64) for change in PEF% p from baseline to week 52 by assessment method. Diagonal line: indicates perfect match; dashed lines: deviation of 20% between methods; filled circles: 8 patients for whom the change in PEF% p over the 12-month study period deviated more than 20% between assessment methods.](jnd-5-jnd180338-g006){#jnd-5-jnd180338-g006}

We also performed sensitivity analyses for the window-based approach by applying differing width of the analysis window around hospital visits (2, 3, or 4-week windows before and after a hospital visit). As shown in [Table 3](#jnd-5-jnd180338-t003){ref-type="table"}, comparable results were obtained, indicating that a short observation of several weeks already provides a reliable assessment of the changes in PEF% p.

Trajectories for the change from baseline in PEF% p for each treatment group were comparable between the spirometry-based measures and those obtained weekly at home using the HHD ([Fig. 7](#jnd-5-jnd180338-g007){ref-type="fig"}).

![Change in PEF% p obtained by weekly HHD compared with hospital-based spirometry results by treatment group.](jnd-5-jnd180338-g007){#jnd-5-jnd180338-g007}

Although mean HHD-data show variability from week to week, their change by treatment group is well in line to what is recorded by hospital spirometry, resulting in clearly diverging trajectories for PEF% p for the idebenone and placebo treatment groups for the study period. Of particular relevance is the observation that 95% confidence intervals from data obtained with spirometry and those obtained by the HHD are overlapping, demonstrating that both assessment methods for PEF% p were congruent and mutually supportive.

DISCUSSION {#sec0065}
==========

This study is the first report on the feasibility of a hand-held device for frequent home-based monitoring of pulmonary function in patients with DMD. Our data demonstrate that the weekly use of a HHD was well accepted by adolescent trial participants over the course of 1 year, with average compliance exceeding 75%, which compares well to a recent study with HHD use in adult patients with COPD \[[@ref029]\]. The findings of this study have implications on the planning of future clinical trials aimed to assess the therapeutic potential of drug candidates on pulmonary function outcomes in patients with DMD. As demonstrated here, results obtained by hospital spirometry for the primary outcome of the DELOS trial, the change in PEF% p, were independently supported by results obtained with the HHD. Although numerical differences for spirometry-measured and HHD-measured outcomes are observed, the point estimates for the between-group differences are of similar magnitude and consistently demonstrated a treatment effect in favour of idebenone in preserving PEF% p compared to placebo. Despite the limited sample size of 31 and 33 patients per treatment group, this consistency of findings across different analysis methods for the HHD-derived data is encouraging and independently supports the positive result for the primary endpoint of the DELOS trial demonstrating that idebenone slowed pulmonary function loss in patients with DMD. Similar approaches whereby HHD-derived pulmonary function data were used to support clinical trial findings obtained by hospital spirometry were previously reported for more common pulmonary diseases, such as COPD in adult patients \[[@ref029]\].

###### 

Influence of the window size on outcomes for change in PEF% p by treatment group

  Window Size        Treatment group (n)    PEF% p (baseline)[^1^](#tfn2){ref-type="table-fn"}   Change from baseline to week 52[^2^](#tfn3){ref-type="table-fn"}   Treatment Difference at week 52[^2^](#tfn3){ref-type="table-fn"}   Treatment Difference Overall [^2^](#tfn3){ref-type="table-fn"},[^3^](#tfn4){ref-type="table-fn"}
  ----------------- ---------------------- ---------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------
  2 weeks            Idebenone (*n* = 31)                      53.1 (12.3)                                            --1.95 (--6.56, 2.66)                                         7.73 (1.30, 14.16) *p* = 0.0192                                                     5.19 (0.80, 9.58) *p* = 0.0212
                      Placebo (*n* = 31)                       52.5 (14.9)                                           --9.68 (--14.15, --5.20)                                                                                         
  3 weeks            Idebenone (*n* = 31)                      53.1 (12.3)                                            --1.77 (--6.38, 2.84)                                         7.24 (0.82, 13.66) *p* = 0.0277                                                     4.72 (0.45, 8.99) *p* = 0.0310
  (main analysis)     Placebo (*n* = 31)                       51.8 (14.8)                                           --9.01 (--13.48, --4.55)                                                                                         
  4 weeks            Idebenone (*n* = 31)                      52.8 (12.6)                                            --1.39 (--6.10, 3.32)                                         7.63 (1.06, 14.21) *p* = 0.0236                                                     4.98 (0.65, 9.30) *p* = 0.0248
                      Placebo (*n* = 31)                       51.7 (14.6)                                           --9.03 (--13.61, --4.44)                                                                                         

1: data is mean (SD);

2: data is estimated mean from MMRM (95% CI);

3: for the treatment difference overall, all post-baseline values were included in the model.

HHD-based pulmonary function testing also has the potential for being used in the setting of clinical practice monitoring to support patient care. Although regular hospital-based monitoring of pulmonary function is recommended by standard of care guidelines \[[@ref002]\], compliance is generally poor \[[@ref021]\]. Explanations for the limited compliance to regular pulmonary function testing could be that physicians do not recommend testing, or patients are not followed in specialized neuromuscular centres where pulmonary function tests are available and recommended. In this regard it should be emphasized that the approach to use HHD-measured pulmonary function data for routine monitoring of disease progression is not limited to the type/brand of device used in this study. In fact, several manufacturers offer suitable devices and provide applications for data analysis and transfer. Certain devices also offer the possibility to collect data for forced vital capacity (FVC), a volume-related pulmonary function measure routinely monitored in patients with DMD. The use of any type of HHD must be accompanied by detailed instructions to the patients and caregivers to ensure reliable pulmonary function measure. This training of patients and caregivers is critical in maximizing the potential for high quality and usable data.

In the current study, patients were advised to use the HHD once per week at home to collect pulmonary function data. However, it could be argued that more frequent (e.g. daily) assessment would offer advantages, particularly an increased number of data points available for interpretation. Moreover, daily use of a HHD would also heighten the awareness for pulmonary aspects of the disease, especially in younger patients where pulmonary function is in the early phase of decline or has not yet reached clinically relevant thresholds. In this regard, daily use of the device could be justified by the short duration (few minutes only) of HHD-based pulmonary testing manoeuvres. However, in patients who already are dependent on the use of cough-assist or ventilator support devices, the additional use of HHD could be seen as extra-burden, limiting its acceptance and adherence. For such patients a testing interval of 1 week as studied here should still be acceptable.

In summary, this study demonstrated that home-based pulmonary function testing using a HHD is feasible in DMD patients at age 10--18 years. It should be noted that patients enrolled in the DELOS trial were already in an advanced stage of the disease, as seen in the high proportion of patients who were non-ambulant at baseline and the degree of upper limb weakness \[[@ref014]\]. The overall good adherence with the use of the HHD over the course of 1 year indicates that this method could potentially be introduced also for routine monitoring of pulmonary function in the context of patient care. The results shown here also demonstrate that HHD-derived data supported the result of the primary endpoint of the DELOS trial, the change to week 52 in PEF% p, although it is acknowledged that spirometry-based and HHD-based pulmonary function testing outcomes are not independent measures of respiratory function. Specifically, several different analysis methods of HHD-derived data demonstrated a consistent, statistically significant benefit in favour of idebenone in preserving PEF% p compared to the placebo group, which followed the expected natural rate of decline \[[@ref019]\]. This is the first randomized, controlled clinical trial in DMD in which HHD-derived data were pre-planned as an independent validation of the primary, spirometry-based study endpoint.
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